ライフサイエンスコーパス: transgender

1 tionnaire (36.3%; 58.6% women, 41% men, 0.4% transgender).

2 proximately 1.4 million persons, identify as transgender.

3 ts (2%) did not identify as male, female, or transgender.

4 s, and 0.10% (0.06-0.12) were women who were transgender.

5 States, ~1.4 million individuals identify as transgender.

6 ent of natal male PATS identified other than transgender.

7 lion people in the United States identify as transgender.

8 al of 60 participants (35 female, 22 male, 1 transgender, 2 undeclared) with social anxiety disorder

9 Many transgender adolescents experience gender dysphoria rela

10 Clinicians involved in the care of transgender adult patients should be knowledgeable about

11 Hormone therapy should be offered to transgender adult patients, with levels maintained withi

12 In addition, many studies of transgender adults focus predominantly on younger person

13 A total of 15 637 transgender adults were identified based on a previously

14 For transgender adults, CSHT has been associated with the po

15 miting the generalizability of CSHT in older transgender adults.

16 e insight into the association between being transgender and cardiovascular risk factors, as well as

17 Third, transgender and cisgender children's patterns of gender

18 While it is becoming increasingly common for transgender and gender non-binary individuals to block t

19 TTMW scores and intervention effects between transgender and gender-diverse and cisgender participant

20 It is unclear whether transgender and gender-diverse individuals have elevated

21 Compared to cisgender individuals, transgender and gender-diverse individuals have, on aver

22 both autistic and non-autistic individuals, transgender and gender-diverse individuals score, on ave

23 ancer prevention, care, and survivorship for transgender and gender-diverse individuals.

24 alth care and tailoring adequate support for transgender and gender-diverse individuals.

25 pregnancy, and to children, adolescents, and transgender and gender-diverse individuals.

26 tate policies targeting gender minority (GM; transgender and gender-diverse) people may affect the me

27 n consultations for surgical therapy to help transgender and gender-nonconforming individuals.

28 ucted to study the association between being transgender and myocardial infarction after adjusting fo

29 A total of 315 transgender and nonbinary participants 12 to 20 years of

30 6%) resulted in inpatient admission, and 171 transgender and nonbinary youth (51%) received inpatient

31 ese effects persisted for 3 months, and both transgender and nontransgender canvassers were effective

32 sation, recent anti- lesbian, gay, bisexual, transgender and queer (LGBTQ+) legislation threatens the

33 Prevalence rates of persons identifying as transgender and seeking help with transition have been r

34 he cross-sectional association between being transgender and the reported history of myocardial infar

35 the association between gender (cisgender or transgender) and (1) retention in care and (2) viral sup

36 respondents were cisgender, 7994 (0.7%) were transgender, and 12 611 (1.0%) preferred not to say thei

37 h (WPATH) standards of care for transsexual, transgender, and gender non-conforming people (version 7

38 dards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People by the Worl

39 ealth disparities in lesbian, gay, bisexual, transgender, and queer (LGBTQ+) communities has been a s

40 unting evidence that lesbian, gay, bisexual, transgender, and queer or questioning (LGBTQ) adults exp

41 Moreover, transgender astrocytes and microglia made up 1-2% of all

42 In the past 10-15 years, paediatric transgender care has emerged at the forefront of several

43 er expression) in a cohort of 3- to 12-y-old transgender children (n = 317) who, in early childhood,

44 there should be a diagnosis of any sort for transgender children below the age of puberty.

45 ity or preferences as a function of how long transgender children had lived as their current gender.

46 First, transgender children strongly identify as members of the

47 Second, transgender children's gender identity (i.e., the gender

48 Dedicated transgender clinics are planned to provide comprehensive

49 f 46 911 cisgender adults was matched to the transgender cohort in a 3:1 ratio based on age and geogr

50 data, and effective partnerships with local transgender communities to ensure responsiveness of and

51 ehensive care to the lesbian, gay, bisexual, transgender community were predictors of MRSA.

52 toward the LGBT (lesbian, gay, bisexual, and transgender) community, and gender equality.

53 This is because of a lack of robust transgender data collection and research, especially wit

54 e genomic DNA of 13 transgender males and 17 transgender females.

55 by a clinician instead of self-identified as transgender [g = 0.193; 95% CI (0.086; 0.300)].

56 The World Professional Association for Transgender Health (WPATH) standards of care for transse

57 ata serve as promising data sources to study transgender health at a population level in the absence

58 est evidence supports introducing modules on transgender health early during clinical education of cl

59 Experts in each aspect of transgender health have summarized the content of the gl

60 The World Professional Association for Transgender Health started a global education initiative

61 Consideration of transgender health underscores the need to explicitly co

62 programming for health-care professionals in transgender health, although the best evidence supports

63 le by the World Professional Association for Transgender Health, including mental health, endocrinolo

64 d roles of the mental health professional in transgender health-care decisions, effective models of h

65 rship can be ambiguous (e.g., multiracial or transgender identities) and because different categorica

66 eta-analysis clarify the association between transgender identity and 2D:4D indicating the influence

67 4D), a proxy for prenatal androgen load, and transgender identity have been inconsistent.

68 ing aged 21-30 years and reporting female or transgender identity.

69 .0%) preferred not to say their cisgender or transgender identity.

70 ant results were revealed for female-to-male transgender individuals [mean age: 26.1 (18; 53)] versus

71 sitive participants (740 men, 1008 women, 78 transgender individuals and 437 unspecified sex) and 994

72 magnitude of the difference in 2D:4D between transgender individuals and controls.

73 nt improvements both in social acceptance of transgender individuals as well as access to gender affi

74 potential brain and cognitive differences in transgender individuals at baseline and after GAHT.

75 rming hormone and surgical interventions for transgender individuals experiencing gender incongruence

76 ion to provide gender-affirming surgeries to transgender individuals who seek them.

77 In this first total population study of transgender individuals with a gender incongruence diagn

78 f 464 participants, we compared the 2D:4D of transgender individuals with age- and sex-matched contro

79 mic among MSM and transwomen (male-to-female transgender individuals) in Lima, Peru, as a test case.

80 required to provide optimal health care for transgender individuals.

81 essment and treatment of gender dysphoria in transgender individuals.

82 o help guide the treatment and management of transgender individuals.

83 at favor men over women, gays, lesbians, and transgender individuals?

84 l, infectious, and psychosocial issues among transgender kidney transplant donors and recipients.

85 Thus, transgender kidney transplant patients can present novel

86 es (January 2014-December 2018) comprising 4 transgender kidney transplant recipients and 2 transgend

87 tolerance toward lesbian, gay, bisexual, and transgender (LGBT) communities, several nations have pro

88 perienced by the lesbian, gay, bisexual, and transgender (LGBT) community and makes a series of recom

89 Lesbian, gay, bisexual, and transgender (LGBT) individuals experience health and hea

90 ansgender kidney transplant recipients and 2 transgender living donors was constructed and analyzed.

91 le exome sequencing on the genomic DNA of 13 transgender males and 17 transgender females.

92 phosphate (TFV-DP) concentrations in TGW and transgender men (TGM) using gender affirming hormones an

93 Multivariable analysis revealed that transgender men had a >2-fold and 4-fold increase in the

94 ion in the study of testosterone therapy for transgender men is a paucity of high-quality data due to

95 many of these individuals self-describing as transgender men or women.

96 ylaxis, interventions for cisgender men with transgender men partners, or cisgender men with casual o

97 with increases in morbidity or mortality in transgender men receiving CSHT.

98 py is a cornerstone of medical treatment for transgender men who choose to undergo it.

99 tudy (mean [range] age, 32 [18-57] years; 17 transgender men, 11 transgender women, and 4 nonbinary p

100 %) were transgender women, 2541 (31.3%) were transgender men, 1507 (18.6%) were non-binary, and 1101

101 3 (34.2%) transgender women, and 237 (23.6%) transgender men.

102 ansgender women compared with cisgender (non-transgender) men who have sex with men (cis-MSM) in 8 su

103 In the HIV pandemic, cisgender (ie, non-transgender) men with transgender partners are an unders

104 nized) left-hand 2D:4D in the male-to-female transgender (MtF) identity [mean age: 32.3 (18; 61)] tha

105 Similarly, transgender nematodes-animals that appear morphologicall

106 Transgender neurons accounted for 1% of all neurons; the

107 d male sex at birth, 937 (20%) identified as transgender or female, and 3,649 were cis-MSM.

108 re cisgender men, and 47 (0.8%) of 6217 were transgender or non-binary people.

109 8 (1.2%) as female gender, and 278 (7.2%) as transgender or non-binary.

110 (40%) for cisgender males, and 336 (7%) for transgender or nonbinary youth.

111 imately 24 years, with no difference between transgender participants and cis-MSM.

112 Transgender participants were less likely to report CAI

113 articipation and clinical characteristics of transgender participants.

114 ic, cisgender (ie, non-transgender) men with transgender partners are an underserved population.

115 Cisgender men with transgender partners are not easily categorised using tr

116 r psychological evaluation is warranted in a transgender patient requesting gender-affirming hormones

117 ng survey assessment v 38.9% postsurvey) and transgender patients (36.9% v 19.5% postsurvey).

118 Similar to other marginalized populations, transgender patients commonly experience discrimination

119 Four transgender patients identified as male-to-female and 2

120 logy, gynaecology and urology are caring for transgender patients in increasing numbers.

121 primary medical and preventive health care, transgender patients need access to gender-affirming int

122 Acne is a common condition among transgender patients on MHT, with a prevalence increasin

123 Acne is a common condition among transgender patients receiving masculinizing hormone the

124 A total of 37 transgender patients with cancer were assessed (mean [SD

125 with kidney transplantation and donation in transgender patients.

126 4.3% used instruments partially-validated in transgender patients.

127 he social and legal conditions in which many transgender people (often called trans people) live, and

128 t currently frames health-care provision for transgender people across much of the world is under scr

129 that frame the provision of health care for transgender people across much of the world.

130 Transgender people are a diverse population affected by

131 y soon abandon its current classification of transgender people as mentally disordered.

132 characterise the population-level health of transgender people globally.

133 We examine research showing that many transgender people live on the margins of society, facin

134 Modern research shows much higher numbers of transgender people than were apparent in earlier clinic-

135 The women, men, and transgender people who sell sex globally have disproport

136 an important gap in national HIV data about transgender people with HIV.

137 sues and provide better legal protection for transgender people, but this action is by no means unive

138 Some clinical services for transgender people, including gender-affirming surgery,

139 urrounding health risks and resiliencies for transgender people.

140 on, and available surgical interventions for transgender people.

141 al or transactional sexual partnerships with transgender people.

142 Transgender persons are a diverse group whose gender ide

143 Forty percent of transgender persons endorse suicidality, and the rate of

144 hts and media attention, the reality is that transgender persons experience health disparities, and a

145 ual factors contributing to mental health in transgender persons include community attitudes, societa

146 clinical practice guideline for the care of transgender persons on the basis of the best available e

147 has been made in characterizing the needs of transgender persons wishing to transition to their prefe

148 testing among men who have sex with men and transgender persons within existing and commonly used so

149 ent care contribute to health disparities in transgender persons, such as increased rates of certain

150 earch has identified autistic traits in some transgender persons.

151 the primary care practitioner in the care of transgender persons.

152 d5) in circumcised, Ad5-seronegative men and transgendered persons who have sex with men in the Unite

153 The medical needs of the transgender population are increasingly recognized withi

154 The transgender population had a higher reported history of

155 Recent studies have reported that the transgender population had a significantly higher rate o

156 re few, and routine surveillance efforts for transgender population health are scarce.

157 scular disease (CVD) and CVD risk factors in transgender populations receiving cross-sex hormone ther

158 their gender identity), existing research in transgender populations suggests that CVD risk factors a

159 although the implementation of services for transgender populations will depend on health system inf

160 sizes and their predominant focus on younger transgender populations.

161 in recruitment of representative samples of transgender populations.

162 The term transgender refers to persons whose gender identity is d

163 ication of Diseases, Tenth Revision (ICD-10) transgender-related diagnosis and procedure codes and se

164 s girls or women, and 5 (2.0%) identified as transgender, reported diverse gender identities, or were

165 sence of survey items with which to identify transgender respondents in general surveys often restric

166 ly to address informal sex workers, male and transgender sex workers, and mobile- and internet-based

167 Because persons who identify across the transgender spectrum (PATS) are a key population in huma

168 has implications for fertility preservation, transgender surgical care and psychosocial health, all o

169 A total of 27 715 TGD adults took the US Transgender Survey, which was disseminated by community-

170 icant difference was also found in mean (SD) transgender warmth scores from baseline to after interve

171 Adolescents identifying as transgender were more than 4 times (OR, 4.44; 95% CI, 0.

172 ts were male (71% versus 28% female and 0.2% transgender), with a mean age of 47 (interquartile range

173 21 818 (74.4%) were male, and 44 (<1%) were transgender, with a median age of 44.3 years (IQR 36.2-5

174 re 9.2 times more likely to link to a second transgender woman than other individuals in the surveill

175 ers, and cisgender individuals linked to one transgender woman were 9.2 times more likely to link to

176 In 2016, the RWHAP served 6,534 transgender women (79.8% retained in care, 79.0% virally

177 (i) cisgender men who have sex with men and transgender women (MSMTW), (ii) cis-heterosexual males,

178 e more likely than expected to link to other transgender women (OR 4.65, p<0.001) and cisgender men w

179 nversion visit, six (18%) of 33 seronegative transgender women (p=0.31), and 58 (52%) of 111 seronega

180 plasma concentrations during PrEP use among transgender women (TGW) using feminizing hormones compar

181 affects men who have sex with men (MSM) and transgender women (TGW).

182 The burden of HIV in transgender women (transwomen) in Brazil remains unknown

183 Prior studies suggest that transgender women (TW) with human immunodeficiency virus

184 etention in care and viral suppression among transgender women accessing the Health Resources and Ser

185 Transgender women across the world face significant vuln

186 diverse sample of 298 sexually active, young transgender women aged 16 through 29 years (mean age, 23

187 Vaccine Impact in Men study surveyed MSM and transgender women aged 18-26 years in 3 US cities during

188 on (OLE) study, men who have sex with men or transgender women aged 18-70 years who were HIV negative

189 A subset of 36 transgender women also participated in qualitative in-de

190 Overall HIV prevalence was 25% (235/926) in transgender women and 14% (505/3,594) in cis-MSM.

191 vestigate differences in PrEP outcomes among transgender women and between transgender women and MSM.

192 acterised the genetically linked partners of transgender women and calculated assortativity (the tend

193 that HIV burden and stigma differed between transgender women and cis-MSM, indicating a need to addr

194 outcomes among transgender women and between transgender women and MSM.

195 ed recent epidemiological research on HIV in transgender women and show that transgender women sex wo

196 Clustering of transgender women and the observed tendency for linkage

197 We set out to identify transgender women and their partners in a molecular tran

198 Our findings suggest that transgender women are a very high burden population for

199 Transgender women are among the groups at highest risk f

200 It is critical to ensure transgender women are aware of and have accurate informa

201 he United States, approximately one-fifth of transgender women are living with HIV-nearly one-half of

202 y one-half of Black/African American (Black) transgender women are living with HIV.

203 youth, including adolescent and young adult transgender women assigned a male sex at birth who ident

204 PrEP group, drug was detected in none of the transgender women at the seroconversion visit, six (18%)

205 taking PrEP, and negatively associated with transgender women community connectedness (multivariable

206 ) and interpersonal (eg, discrimination, low transgender women community connectedness) hardship repo

207 he odds ratio for being infected with HIV in transgender women compared with all adults of reproducti

208 nd behavioral drivers of HIV infection among transgender women compared with cisgender (non-transgend

209 ison to the cisgender population, except for transgender women compared with cisgender men, even afte

210 A total of 182 transgender women completed the questionnaire; most wome

211 parallel mixed methods design, trained local transgender women data collectors recruited 213 transgen

212 159 (28%) transgender women disagreed that they were at risk for H

213 Transgender women experience lifelong gender dysphoria d

214 r more characteristics and are classified as transgender women for the purpose of this study.

215 worldwide burden of HIV; however, data among transgender women from the region are sparse.

216 Conversely, transgender women had >2-fold increase in the rate of my

217 HIV incidence remains high among transgender women in Lima, Peru, most of whom report sex

218 ts urged greater education and engagement of transgender women in PrEP implementation.

219 r to inform PrEP implementation efforts with transgender women in South Africa.

220 Of the 2499 MSM and transgender women in the iPrEx trial, 1251 were assigned

221 tified a high prevalence of HIV infection in transgender women in the USA and in those who sell sex (

222 Other associated conditions commonly seen in transgender women include increased risks of depression

223 Reducing barriers to HIV medical care for transgender women is critical to decrease disparities am

224 The evidence base for the care of transgender women is limited by the paucity of high-qual

225 Compared with MSM, transgender women more frequently reported transactional

226 nsgender women data collectors recruited 213 transgender women participants (aged >18 years, assigned

227 Studies of PrEP use in transgender women populations should be designed and tai

228 and comorbid psychiatric disorders in young transgender women remain scarce.

229 ble participants were HIV-uninfected men and transgender women reporting condomless anal intercourse

230 The overall PAF for MSM and transgender women reporting receptive anal intercourse w

231 In 3869 transgender women sampled in five high-income countries,

232 In 7197 transgender women sampled in ten low-income and middle-i

233 NNTs were lowest for MSM and transgender women self-reporting receptive anal intercou

234 ch on HIV in transgender women and show that transgender women sex workers (TSW) face unique structur

235 del to guide HIV programmatic planning among transgender women sex workers (TWSW) in Lima.

236 udies that assessed HIV infection burdens in transgender women that were published between Jan 1, 200

237 idence of HPV among vaccine-eligible MSM and transgender women to monitor vaccine impact.

238 tive anal sex, the odds of HIV infection for transgender women were 2.2 times greater than the odds f

239 Black transgender women were also less likely to reach viral s

240 Transgender women were assortative in the network (assor

241 Transgender women were distributed across 126 clusters,

242 Transgender women were less likely than expected to link

243 Black transgender women were less likely to be retained in car

244 Transgender women were more likely than expected to link

245 Compared to cis-MSM participants, transgender women were more likely to experience family

246 Transgender women were more likely to report condomless

247 e effective in preventing HIV acquisition in transgender women when taken, but there seem to be barri

248 awareness more frequently than HIV-negative transgender women who did not.

249 Worldwide, transgender women who engage in sex work have a dispropo

250 domly assigned 2499 HIV-seronegative men and transgender women who have sex with men (MSM) to receive

251 In our cohort study, men and transgender women who have sex with men previously enrol

252 ndomly assigned 2499 HIV-seronegative men or transgender women who have sex with men to receive a com

253 t 21 sites, we randomly assigned 2504 men or transgender women who have sex with men to receive the D

254 dult cisgender men who have sex with men and transgender women who have sex with men, both with a hig

255 oxil fumarate among HIV-seronegative men and transgender women who have sex with men: HIV infection w

256 Transgender women who indicated a sexual risk factor clu

257 population level if targeted toward MSM and transgender women who report receptive anal intercourse

258 We found that transgender women who took FHT exhibited a 7-fold lower

259 sters that are likely to include undiagnosed transgender women with HIV and to improve the targeting

260 modelling was used to compare HIV burdens in transgender women with that in adults in the countries f

261 s known about the burden of HIV infection in transgender women worldwide.

262 better assess the relative HIV burden in all transgender women worldwide.

263 lence was 19.1% (95% CI 17.4-20.7) in 11 066 transgender women worldwide.

264 adults (particularly lesbian, bisexual, and transgender women) experience disparities across several

265 hnic minority men who have sex with men, and transgender women).

266 isgender men, 5.0% cisgender women, and 1.3% transgender women); 3,971 of these sequences formed 1,20

267 2960 (36.5%) were transgender women, 2541 (31.3%) were transgender men, 15

268 Of the 298 transgender women, 41.5% of participants had 1 or more m

269 ysis: 423 (42.2%) cisgender men, 343 (34.2%) transgender women, and 237 (23.6%) transgender men.

270 ge, 32 [18-57] years; 17 transgender men, 11 transgender women, and 4 nonbinary participants).

271 For transgender women, CSHT has known thromboembolic risk, a

272 acebo in men who have sex with men (MSM) and transgender women, followed by an open-label extension.

273 ncluding men who have sex with men (MSM) and transgender women, in Bangkok, Thailand and Harlem, New

274 ncluding men who have sex with men (MSM) and transgender women, in Bangkok, Thailand and Harlem, New

275 oup, including men who have sex with men and transgender women, is poorly understood.

276 Among transgender women, there were 11 HIV infections in the P

277 e sex at birth who identify as girls, women, transgender women, transfemale, male-to-female, or anoth

278 to behavioural indicators of HIV risk among transgender women, whereas MSM at highest risk were more

279 commends pre-exposure prophylaxis (PrEP) for transgender women, whose HIV prevalence estimates are as

280 hormone-sensitive cancer seems to be low in transgender women, with no increased risk of breast canc

281 indicating that they tended to link to other transgender women.

282 health prevention and treatment services to transgender women.

283 is in Peruvian men who have sex with men and transgender women.

284 in this community-recruited sample of young transgender women.

285 eronegative men who have sex with men and in transgender women.

286 EP efficacy, effectiveness, and adherence in transgender women.

287 sition of HIV in groups at high risk such as transgender women.

288 acquisition in men who have sex with men and transgender women.

289 in 2499 men who have sex with men (MSM) and transgender women.

290 sks of pre-exposure prophylaxis with MSM and transgender women.

291 and severity of the HIV disease burden among transgender women.

292 and Black participants, cisgender women, and transgender women.

293 vide comprehensive care, including PrEP, for transgender women.

294 rica is poised to scale up PrEP services for transgender women.

295 arities in HIV clinical outcomes among Black transgender women.

296 tes are prepared to provide quality care for transgender women.

297 ble on HIV-related clinical indicators among transgender women.

298 ividuals, including 412 (2%) self-identified transgender women.

299 A significant change in attitudes toward transgender youth was found within the intervention grou

300 Transgender youth, including adolescent and young adult